Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469913 | 0.95 | OPRM1 (0.33) | OPRM1OPRL1MTOR | |
| SCHEMBL24469763 | 0.92 | USP7 (0.33) | MTOR | |
| Trifluoroacetic Acid SCHEMBL29670376 | 0.87 | F11 (0.31) | F11KLKB1 | |
| SCHEMBL24469867 | 0.84 | CRBN (0.36) | OPRM1OPRL1 | |
| SCHEMBL24484130 | 0.82 | CCNC (0.32) | — | |
| SCHEMBL24470105 | 0.81 | USP7 (0.33) | — | |
| SCHEMBL24470063 | 0.81 | MTOR (0.35) | OPRM1OPRL1MTOR | |
| Trifluoroacetic Acid SCHEMBL29670456 | 0.80 | CHRM4 (0.35) | F11KLKB1 | |
| SCHEMBL24469782 | 0.79 | HSP90AA1 (0.35) | MTOR | |
| SCHEMBL24469914 | 0.78 | GPR119 (0.33) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | OPRM1 2045/4885OPRL1 2137/4885F11 1498/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | OPRM1 2045/4885OPRL1 2137/4885F11 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.